Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
May 16 LLY Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial
May 16 LLY Eli Lilly once-weekly insulin hits main goal in late-stage trials
May 16 LLY These 2 No-Brainer Growth Stocks Are Breaking New Ground
May 16 LLY UPDATE 2-Lilly's weekly insulin as effective as daily doses in studies
May 16 LLY With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
May 16 AZN AstraZeneca selects new heart failure target with BenevolentAI
May 15 LLY Dow Jones Futures: Dow, S&P 500, Nasdaq Hit Highs, Nvidia Leads 12 New Buys; What To Do Now
May 15 LLY Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
May 15 LLY Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
May 15 LLY Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
May 15 VNDA Vanda reports positive Phase 3 data for motion sickness drug
May 15 LLY UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
May 15 LLY Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
May 15 ANRO Alto Neuroscience reports Q1 GAAP EPS of -$0.76
May 15 VNDA Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
May 15 LLY Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
May 15 LLY These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
May 14 LLY Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
May 14 LLY Lilly Settles With Spa Selling Mounjaro, Zepbound Knock-Offs
May 14 ANRO Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags